Evidence map›Paper›PMID 28601915›Full record

ArticleClinical oral investigations2018

Volatile organic compounds in the breath of oral candidiasis patients: a pilot study.

Moritz Hertel, Eyke Schuette, Isabell Kastner, Stefan Hartwig, Andrea Maria Schmidt-Westhausen, Robert Preissner, Sebastian Paris, Saskia Preissner

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical oral investigations, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Moritz HertelDepartment of Oral Medicine, Dental Radiology and Oral Surgery, Charité Universitätsmedizin Berlin, Berlin, Germany.
Eyke SchuetteDepartment of Oral Medicine, Dental Radiology and Oral Surgery, Charité Universitätsmedizin Berlin, Berlin, Germany.
Isabell KastnerDepartment of Operative and Preventive Dentistry, Charité Universitätsmedizin Berlin, Berlin, Germany.
Stefan HartwigDepartment of Oral and Maxillofacial Surgery, Charité Universitätsmedizin Berlin, Berlin, Germany.
Andrea Maria Schmidt-WesthausenDepartment of Oral Medicine, Dental Radiology and Oral Surgery, Charité Universitätsmedizin Berlin, Berlin, Germany.
Robert PreissnerStructural Bioinformatics Group, Institute of Physiology, Charité Universitätsmedizin Berlin & ECRC, Berlin, Germany.
Sebastian ParisDepartment of Operative and Preventive Dentistry, Charité Universitätsmedizin Berlin, Berlin, Germany.
Saskia PreissnerDepartment of Operative and Preventive Dentistry, Charité Universitätsmedizin Berlin, Berlin, Germany. saskia.preissner@charite.de.
Charité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of the study was to investigate whether specific volatile organic compounds (VOCs) can be detected in oral candidiasis patients using breath analysis in order to develop a point-of-care diagnostic tool. PATIENTS/

methodsBreath samples of 10 diseased patients and 10 subjects carrying no Candida spp. were analyzed using gas chromatography and mass spectrometry. In infected patients, breath tests were performed before and after antifungal therapy.

resultsBreath testing was positive for 143 volatiles in both healthy subjects and diseased patients. Among those, specific signature volatiles known to be emitted by Candida spp. in vitro were not detected. Even though no specific signature was retrieved from the diseased patients, a pattern containing nine compounds (2-methyl-2-butanol, hexanal, longifolene, methyl acetate, 1-heptene, acetophenone, decane, 3-methyl-1-butanol, chlorbenzene) was identified, which showed characteristic changes after antifungal therapy.

conclusionsFocusing on the identified pattern, breath analysis may be applied to confirm the absence of Candida spp. after therapy in terms of a confirmatory test supplementing clinical examination, thereby replacing microbial testing. However, microbial testing will still be needed to initially confirm clinical diagnoses, as no specific signature was found. CLINICAL RELEVANCE: A breath test may help in avoiding extended antifungal administration resulting in resistance development and might be useful in the monitoring of disease recurrences in vulnerable groups.

Indexed as

AgedAged, 80 and overAntifungal AgentsBreath TestsCandidiasis, OralCase-Control StudiesDenturesFemaleGas Chromatography-Mass SpectrometryHumansMaleMass SpectrometryMiddle AgedPilot ProjectsVolatile Organic CompoundsAntifungal AgentsVolatile Organic CompoundsBreath testFungal infectionGC/MSOral candidiasisOropharyngeal candidiasisVolatile organic compounds

Identifiers

PMID28601915
OpenAlexW2622115717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.